Market Research Logo

Colon Cancer - Pipeline Review, H1 2018

Colon Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H1 2018, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 12, 40, 3, 169, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 43 and 15 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Colon Cancer - Overview
Colon Cancer - Therapeutics Development
Colon Cancer - Therapeutics Assessment
Colon Cancer - Companies Involved in Therapeutics Development
Colon Cancer - Drug Profiles
Colon Cancer - Dormant Projects
Colon Cancer - Discontinued Products
Colon Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Colon Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Colon Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
Colon Cancer - Pipeline by 4P-Pharma SAS, H1 2018
Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
Colon Cancer - Pipeline by Adamed Sp z oo, H1 2018
Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018
Colon Cancer - Pipeline by Aduro BioTech Inc, H1 2018
Colon Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
Colon Cancer - Pipeline by Affimed GmbH, H1 2018
Colon Cancer - Pipeline by AGV Discovery SAS, H1 2018
Colon Cancer - Pipeline by AIMM Therapeutics BV, H1 2018
Colon Cancer - Pipeline by AlfaSigma SpA, H1 2018
Colon Cancer - Pipeline by Alligator Bioscience AB, H1 2018
Colon Cancer - Pipeline by Ambrx Inc, H1 2018
Colon Cancer - Pipeline by Amgen Inc, H1 2018
Colon Cancer - Pipeline by AndroScience Corp, H1 2018
Colon Cancer - Pipeline by ANP Technologies Inc, H1 2018
Colon Cancer - Pipeline by Aphios Corp, H1 2018
Colon Cancer - Pipeline by Aptose Biosciences Inc, H1 2018
Colon Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
Colon Cancer - Pipeline by Asana BioSciences LLC, H1 2018
Colon Cancer - Pipeline by aTyr Pharma Inc, H1 2018
Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Colon Cancer - Pipeline by Batu Biologics Inc, H1 2018
Colon Cancer - Pipeline by Bayer AG, H1 2018
Colon Cancer - Pipeline by BCN Biosciences LLC, H1 2018
Colon Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
Colon Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2018
Colon Cancer - Pipeline by BioCancell Ltd, H1 2018
Colon Cancer - Pipeline by Biogazelle NV, H1 2018
Colon Cancer - Pipeline by Blirt SA, H1 2018
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Colon Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2018
Colon Cancer - Pipeline by Celgene Corp, H1 2018
Colon Cancer - Pipeline by Cellective BioTherapy Inc, H1 2018
Colon Cancer - Pipeline by Celprogen Inc, H1 2018
Colon Cancer - Pipeline by Chem-Master International Inc, H1 2018
Colon Cancer - Pipeline by CytomX Therapeutics Inc, H1 2018
Colon Cancer - Pipeline by Cytune Pharma SAS, H1 2018
Colon Cancer - Pipeline by CZ BioMed Corp, H1 2018
Colon Cancer - Pipeline by Debiopharm International SA, H1 2018
Colon Cancer - Pipeline by DEKK-TEC Inc, H1 2018
Colon Cancer - Pipeline by Eli Lilly and Co, H1 2018
Colon Cancer - Pipeline by Enterome Bioscience SA, H1 2018
Colon Cancer - Pipeline by EntreChem SL, H1 2018
Colon Cancer - Pipeline by EnzymeBioSystems, H1 2018
Colon Cancer - Pipeline by Evotec AG, H1 2018
Colon Cancer - Pipeline by F-star Biotechnology Ltd, H1 2018
Colon Cancer - Pipeline by Felicitex Therapeutics Inc, H1 2018
Colon Cancer - Pipeline by Fujifilm Holdings Corporation, H1 2018
Colon Cancer - Pipeline by Fusion Pharmaceuticals Inc, H1 2018
List of Figures
Number of Products under Development for Colon Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report